✦ LIBER ✦

Incidence of atrial fibrillation in a population with impaired glucose tolerance: The contribution of glucose metabolism and other risk factors. A post hoc analysis of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research trial

✍ Scribed by Latini, Roberto; Staszewsky, Lidia; Sun, Jie-Lena; Bethel, M. Angelyn; Disertori, Marcello; Haffner, Steven M.; Holman, Rury R.; Chang, Futien; Giles, Thomas D.; Maggioni, Aldo P.; Rutten, Guy E.H.M.; Standl, Eberhard; Thomas, Laine; Tognoni, Gianni; Califf, Robert M.; McMurray, John J.V.

Book ID: 123046396
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 197 KB
Volume: 166
Category: Article
ISSN: 1097-6744
DOI: 10.1016/j.ahj.2013.08.012

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prevention of diabetes and cardiovascula

Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: Rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial

✍ Robert M. Califf; Mitradev Boolell; Steven M. Haffner; M. Angelyn Bethel; John M 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 346 KB

Baseline Characteristics of the Nateglin

Baseline Characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial Population: Comparison with Other Diabetes Prevention Trials

✍ Henry Krum; John J.V. McMurray; Edward Horton; Teresa Gerlock; Bjoern Holzhauer; 📂 Article 📅 2010 🏛 Hindawi Limited 🌐 English ⚖ 126 KB

Randomised controlled trial evaluating t

Randomised controlled trial evaluating the effectiveness of behavioural interventions to modify cardiovascular risk factors in men and women with impaired glucose tolerance: outcomes at 6 months

✍ J.C Oldroyd; N.C Unwin; M White; K Imrie; J.C Mathers; K.G.M.M Alberti 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 139 KB

Role of gamma-glutamyl transferase (GGT)

Role of gamma-glutamyl transferase (GGT) in diagnosis of impaired glucose tolerance and metabolic syndrome: A prospective cohort research from the Kerman Coronary Artery Disease Risk Study (KERCADRS)

✍ Yousefzadeh, Gholamreza; Shokoohi, Mostafa; Yeganeh, Mahboobeh; Najafipour, Hami 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 332 KB

Acarbose for the prevention of Type 2 di

Acarbose for the prevention of Type 2 diabetes, hypertension and cardiovascular disease in subjects with impaired glucose tolerance: facts and interpretations concerning the critical analysis of the STOP-NIDDM Trial data

✍ J.-L. Chiasson; R. G. Josse; R. Gomis; M. Hanefeld; A. Karasik; M. Laakso; the S 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 147 KB

Effects of 1-year treatment with metform

Effects of 1-year treatment with metformin on metabolic and cardiovascular risk factors in non-diabetic upper-body obese subjects with mild glucose anomalies: A post-hoc analysis of the BIGPRO1 trial

✍ A. Fontbonne; I. Diouf; M. Baccara-Dinet; E. Eschwege; M.-A. Charles 📂 Article 📅 2009 🏛 Masson Editeur 🌐 French ⚖ 243 KB